NCT07145450 - Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

April 2, 2030

Study Completion Date

July 31, 2030

Conditions

PDAC

Interventions

BIOLOGICAL

ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)

"The cells will be gene edited and administered by a single IV infusion on Day 1.~Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy."

BIOLOGICAL

ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)

The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.

BIOLOGICAL

ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)

The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy

Trial Locations (8)

Unknown

ACTIVE_NOT_RECRUITING

Herlev and Gentofte University Hospital, Copenhagen

ACTIVE_NOT_RECRUITING

Charité Universitätsmedizin Berlin, Berlin

RECRUITING

Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus, Dresden

ACTIVE_NOT_RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

ACTIVE_NOT_RECRUITING

University Hospital and Faculty of Medicine Eberhard Karls University Tübingen, Tübingen

ACTIVE_NOT_RECRUITING

Amsterdam UMC - VU Medical Center, Amsterdam

ACTIVE_NOT_RECRUITING

Radboud University Medical Center, Nijmegen

RECRUITING

Karolinska University Hospital, Stockholm